CompletedPhase 2NCT00513435

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Matthew Fury, MD
Memorial Sloan Kettering Cancer Center
Intervention
saracatinib(drug)
Enrollment
9 enrolled
Eligibility
18 years · All sexes
Timeline
20072011

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00513435 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials